87291-34-7

Basic information

• Product Name: 1-(2-chloroethoxy)-3-nitrobenzene
• Synonyms: 1-(2-chloroethoxy)-3-nitrobenzene;3-(2-CHLOROETHOXY)NITROBENZENE
• CAS NO: 87291-34-7
• Molecular Formula: C₈H₈ClNO₃
• Molecular Weight: 201.61
• Mol File: 87291-34-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2-chloroethoxy)-3-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloroethoxy)-3-nitrobenzene(87291-34-7)
• EPA Substance Registry System: 1-(2-chloroethoxy)-3-nitrobenzene(87291-34-7)

Safety Data

• Hazardous Substances Data: 87291-34-7(Hazardous Substances Data)

Usage

General Description

1-(2-chloroethoxy)-3-nitrobenzene is a chemical compound with the molecular formula C8H8ClNO3. It is a nitrobenzene derivative containing a chlorine atom and an ethoxy group, which consists of an ethyl group attached to an oxygen atom. The compound is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the production of dyes and pigments. The presence of both a nitro group and a chlorine atom in the compound makes it potentially hazardous, and it is important to handle and store it with caution to avoid any harmful effects on human health or the environment.

Upstream product

• 554-84-7 meta-nitrophenol 
• 107-07-3 2-chloro-ethanol 
• 78-93-3 butanone 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 890652-00-3 3-(2-(4-methylpiperazin-1-yl)ethoxy)aniline 
• 891856-25-0 1-methyl-4-(2-(3-nitrophenoxy)ethyl)piperazine 
• 925450-69-7 1-[2-(2-Chloroethoxy)-6-nitrophenylmethanesulfonyl]naphthalene 
• 742662-24-4 N-[3-(2-Imidazol-1-yl-ethoxy)-phenyl]-guanidine 

Relevant articles and documents

Design, synthesis, and biological study of 4-[(2-nitroimidazole-1h-alkyloxyl)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia

Purpose: In order to get novel EGFR inhibitors exerting more potency in tumor hypoxia than in normoxia. Methods: A series of 4-[(2-nitroimidazole-1H-alkyloxyl)aniline]-quinazolines were designed and synthesized, and their in vitro cytotoxicity and EGFR inhibitory activity were evaluated. Molecule docking study was performed for the representative compound. Results: The structure-activity relationship (SAR) studies revealed that compounds bearing both meta-chloride and para-(2-nitroimidazole-1H-alkyloxy) groups on the aniline displayed potent inhibitory activities both in enzymatic and cellular levels. The most promising compound 16i potently inhibited EGFR with an IC50 value of 0.12 μM. Meanwhile, it manifested more potent cytotoxicity than the positive control lapatinib under tumor normoxia and hypoxia conditions (IC50 values of 1.59 and 1.09 μM against A549 cells, 2.46 and 1.35 μM against HT-29 cells, respectively). The proposed binding model of 16i in complex with EGFR was displayed by the docking results. Conclusion: This study provides insights for developing hypoxia-activated kinase inhibitors.

2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors

The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.

Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.